Transaction DateRecipientSharesTypePriceValue
6th October 2020Partners L P/Il Bvf157,782Open or private purchase$5.04$794,432.37
6th October 2020Partners L P/Il Bvf162,352Open or private purchase$5.04$817,442.32
6th October 2020Partners L P/Il Bvf25,107Open or private purchase$5.04$126,413.75
23rd September 2020Partners L P/Il Bvf7,201Open or private purchase$18.20$131,056.76
23rd September 2020Partners L P/Il Bvf9,888Open or private purchase$18.20$179,959.62
22nd September 2020Partners L P/Il Bvf32Open or private purchase$3.80$121.56
22nd September 2020Partners L P/Il Bvf6,960Open or private purchase$18.45$128,382.07
22nd September 2020Partners L P/Il Bvf4,991Open or private purchase$18.45$92,062.49
21st September 2020Partners L P/Il Bvf10,069Open or private purchase$18.39$185,119.57
21st September 2020Partners L P/Il Bvf12,259Open or private purchase$18.39$225,382.94
Glyco Mimetics
Glyco Mimetics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


GlycoMimetics, Inc. focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003.


Ticker: GLYC
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1253689
Employees: 57
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $150 M (-5%)
Assets, Current: $153 M (-5%)
Property, Plant and Equipment, Net: $708 Th (0%)
Assets: $158 M (-5%)
Accounts Payable, Current: $1 M (-4%)
Accrued Liabilities, Current: $7 M (0%)
Liabilities, Current: $10 M (-11%)
Liabilities: $13 M (-8%)
Common Stock, Value, Issued: $47 Th (7%)
Common Stock, Shares, Issued: $47 M (7%)
Retained Earnings (Accumulated Deficit): $280 M (8%)
Stockholders' Equity (Parent): $146 M (0%)
Liabilities and Equity: $158 M (-5%)
Research and Development: $10 M (-56%)
General and Administrative Expenses: $4 M (-51%)
Operating Income/Loss: $14 M (-36%)